EVALUACIÓN DE LA CALIDAD DE VIDA DE LOS PACIENTES CON CÁNCER DE PULMÓN NO MICROCÍTICO METASTÁSICO CON TERAPIA SUPLEMENTARIA CON IGEN-0206.

18F-FDG-PET/CT response after first-line treatment as a prognostic factor for survival in peripheral T-cell lymphoma: a Spanish retrospective study.

Cordoba, Raul; (...); Martin Garcia-Sancho, Alejandro

Article. 10.1080/17474086.2024.2313457. 2024

A Descriptive Study of 103 Primary Cutaneous B-Cell Lymphomas: Clinical and Pathological Characteristics and Treatment from the Spanish Lymphoma Oncology Group (GOTEL).

Martínez-Banaclocha N; (...); Gumà J

Article. 10.3390/cancers16051034. 2024

• 
• 2

  

Agreement Between Different Methodologies for Non-Invasive p.T790M and EGFR Sensitizing Mutation Testing

Romero, A; (...); Provencio, M

Meeting Abstract. 10.1016/j.jtho.2019.08.1463. 2019

Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study

Conde, E; (...); Lopez-Rios, F

Article. 10.1016/j.jtho.2019.07.005. 2019

• 
• 
• 64

  

Assessment of Gender Differences in the Psychosocial and Economic Impact on Patients with Stage IV Non-Small Cell Lung Cancer

Garrido, P; (...); Vinolas, N

Meeting Abstract. 10.1016/j.jtho.2019.08.685. 2019

ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort.

Vicente-Baz D; (...); Provencio M

Article. 10.1016/j.patol.2019.11.002. 2020

• 
• 1

  

ATEZO-BRAIN, A Single-Arm Phase II Study of Atezolizumab Combined with Chemotherapy in Stage IV NSCLC Patients with Untreated Brain Metastases

Nadal, E; (...); Bruna, J

Meeting Abstract. 10.1016/j.jtho.2019.08.826. 2019

• 1

  

CD8+ NKs as a potential biomarker of complete response and survival with lenalidomide plus R-GDP in the R2-GDP-GOTEL trial in recurrent/refractory diffuse large B cell lymphoma.

Hontecillas-Prieto L; (...); de la Cruz-Merino L

Article. 10.3389/fimmu.2024.1293931. 2024

• 
• 
• 3

  

Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial

Jimenez-Cortegana, C; (...); de la Cruz-Merino, L

Article. 10.1136/jitc-2020-002323. 2021

• 
• 
• 37

  

Clinical and pathological characteristics of peripheral T-cell lymphomas in a Spanish population: a retrospective study.

Rodriguez-Pinilla SM; (...); Cordoba, Raul

Article. 10.1111/bjh.16741. 2021

• 
• 
• 8

  

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

Zugazagoitia, J; (...); Garrido, P

Article. 10.1016/j.lungcan.2019.05.032. 2019

• 
• 25

  

Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

Provencio, M; (...); Rueda, A

Letter. 10.1080/10428194.2018.1509322. 2019

• 
• 5

  

CXCR7 reactivates ERK signaling to promote resistance to EGFR kinase inhibitors in NSCLC.

Becker JH; (...); Shimamura T

Article. 10.1158/0008-5472.CAN-19-0024. 2019

• 
• 
• 51

  

Chemokine Receptor CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC

Becker, J; (...); Shimamura, T

Meeting Abstract. 10.1016/j.jtho.2019.08.1478. 2019

Development, Implementation and Assessment of Molecular Diagnostics by Next Generation Sequencing in Personalized Treatment of Cancer: Experience of a Public Reference Healthcare Hospital.

Simarro J; (...); Palanca S

Article. 10.3390/cancers11081196. 2019

• 
• 
• 18

  

Effect of central nervous system (CNS) metastases in a real-world multicenter cohort study of Spanish ALK-positive non-small cell lung cancer (NSCLC) patients (p)

Angelats, L; (...); Costa, EC

Meeting Abstract. 2019

Genetic and Molecular Profiling of Non-Smoking Related Lung Adenocarcinomas

Pros, E; (...); Sanchez-Cespedes, M

Meeting Abstract. 10.1016/j.jtho.2019.08.878. 2019

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors.

Pros E; (...); Sanchez-Cespedes M

Article. 10.1016/j.annonc.2019.09.001. 2020

• 
• 
• 46

  

Impact of Molecular Testing Using Next-Generation Sequencing in the Clinical Management of Patients with Non-Small Cell Lung Cancer in a Public Healthcare Hospital.

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/cancers15061705. 2023

• 
• 
• 10

  

Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer

Rodriguez, LPA; (...); Bunn, P

Meeting Abstract. 2019

Lenalidomide plus R-GDP (R2-GDP) in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Final Results of the R2-GDP-GOTEL Trial and Immune Biomarker subanalysis.

Palaz N-Carri N, Natalia; (...); de la Cruz-Merino, Luis

Article. 10.1158/1078-0432.CCR-22-0588. 2022

• 
• 
• 12

  

Lenalidomide plus R-GDP (R2-GDP) in relapsed/refractory diffuse large B-cell lymphoma: Final results of the R2-GDP-GOTEL trial.

Merino, LD; (...); Dominguez, AR

Meeting Abstract. 2020

Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients.

González-Barca E; (...); de Sevilla AF

Article. 10.1007/s00277-020-04056-9. 2020

• 
• 12

  

Metastases Sites as a Prognostic Factor in a Real-World Multicenter Cohort Study of Spanish ALK-Positive NSCLC Patients (p)

Angelats, L; (...); Carcereny, E

Meeting Abstract. 10.1016/j.jtho.2019.08.808. 2019

MS201944-0170: A phase Ila study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.

Ciardiello, Fortunato; (...); Galffy, Gabriella

Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.TPS9123. 2019

Multicenter Study of the Seroprevalence of Antibodies against Covid-19 in Patients with Lymphoma: An Analysis of the Oncological Group for the Treatment and Study of Lymphomas (Gotel)

Franco, F; (...); Provencio, M

Article. 10.3390/curroncol28020118. 2021

• 
• 
• 2

  

Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases

Ponce, S; (...); Nadal, E

Review. 10.1016/j.critrevonc.2019.03.017. 2019

• 
• 8

  

Nab-Paclitaxel Maintenance in Squamous Non-Small Cell Lung Cancer (NSCLC): Updated Results of the Phase III ABOUND.sqm Study

Spigel, D; (...); Thomas, M

Meeting Abstract. 10.1016/j.jtho.2019.08.604. 2019

Opioid-Induced Constipation in Oncological Patients: New Strategies of Management.

Mesía R; (...); Pujol E

Article. 10.1007/s11864-019-0686-6. 2019

• 
• 
• 34

  

Oral vinorelbine versus etoposide with cisplatin and chemo-radiation as treatment in patients with stage III non-small cell lung cancer: A randomized phase II (RENO study).

Isla D; (...); Provencio M

Article. 10.1016/j.lungcan.2018.11.041. 2019

• 
• 9

  

Pain Standards for Accredited Healthcare Organizations (ACDON Project): A Mixed Methods Study.

Perez, Concepcion; (...); Mira, Jose J.

Article. 10.3390/jpm11020102. 2021

• 
• 
• 1

  

Peripheral T-cell lymphoma with a T follicular-helper phenotype: A different entity? Results of the Spanish Real-T study.

Martin Garcia-Sancho, Alejandro; (...); Cordoba, Raul

Article. 10.1111/bjh.18941. 2023

• 
• 
• 5

  

Phase II study of durvalumab (MEDI4736) in cancer patients HIV-1-infected.

Gonzalez-Cao, M; (...); Rosell, R

Meeting Abstract. 10.1200/JCO.2019.37.15_suppl.2501. 2019

• 17

  

Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)

Vidal, OJJ; (...); Palanca, S

Meeting Abstract. 2019

Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma.

Pedrosa, Lucia; (...); Sanchez-Beato, Margarita

Article. 10.1038/s41598-020-80376-0. 2021

• 
• 
• 36

  

Real Clinical Practice Study to Evaluate 2 Line Treatment Based on Comprenhensive Genomic Profiling in NSCLC. LungONE Study

Carpeno, JD; (...); Rojo, F

Meeting Abstract. 2019

RESILIENT: Study of irinotecan liposome injection (nal-IRI) in patients with small cell lung cancer-Preliminary findings from part 1 dose-defining phase.

Paz-Ares, Luis G.; (...); Bunn, Paul A.

Meeting Abstract. 2019

SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022).

Guma, Josep; (...); Provencio, Mariano

Article. 10.1007/s12094-023-03206-5. 2023

• 
• 
• 3

  

Spanish registry of thoracic tumors (TTR): Interim analyses of comorbidities, risk associations, personal and family history of cancer

Castro, RL; (...); Provencio, M

Meeting Abstract. 2019

Technical Validation and Clinical Implications of Ultrasensitive PCR Approaches for EGFR-Thr790Met Mutation Detection in Pretreatment FFPE Samples and in Liquid Biopsies from Non-Small Cell Lung Cancer Patients

Simarro, Javier; (...); Palanca, Sarai

Article. 10.3390/ijms23158526. 2022

• 
• 3

  

Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

Mendez, M; (...); Provencio, M

Article. 10.1002/hon.2601. 2019

• 
• 12

  

Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

Gonzalez-Rincon, J; (...); Sanchez-Beato, M

Article. 10.1371/journal.pone.0212813. 2019

• 
• 
• 40